Inactive Instrument

Gala Pharmaceutical, Inc.

GLPH

US36316C3043

Gala Pharmaceutical, Inc. Reports Earnings Results for the Second Quarter Ended May 31, 2019

July 23, 2019 at 04:30 pm EDT

Gala Pharmaceutical, Inc. announced earnings results for the second quarter ended May 31, 2019. For the second quarter, the company announced sales was USD 0 compared to USD 4,675 a year ago. Net loss was USD 2.112 million compared to USD 393,746 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago. For the half year, sales was USD 0 compared to USD 4,675 a year ago. Net loss was USD 2.689 million compared to USD 976,988 a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.

Latest news about Gala Pharmaceutical, Inc.

Gala Pharmaceutical, Inc. Announces Executive Changes	19-10-21	CI
Gala Pharmaceutical, Inc. Reports Earnings Results for the Second Quarter Ended May 31, 2019	19-07-23	CI
Gala Pharmaceutical Completes Construction of its Long Beach California Testing Facility	19-06-05	CI
Gala Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2019	19-04-30	CI
Gala Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended November 30, 2018	19-04-15	CI
Gala Pharmaceutical, Inc. Auditor Raises 'Going Concern' Doubt	19-04-14	CI
Gala Pharmaceutical Starts Construction of Its Long Beach California Testing Facility	19-03-14	CI
Gala Pharmaceutical, Inc. Appoints Reiner Hoogenraad as a Member of the Company’s Board of Directors	19-01-03	CI
Gala Pharmaceutical, Inc. Files State License Application for Testing Facility	18-12-07	CI
Gala Pharmaceutical, Inc. Announces Management Changes	18-11-30	CI
Gala Pharmaceutical, Inc. Announces Resignation of Romina Martinez as Director	18-10-03	CI
Gala Pharmaceutical to Form Strategic Alliances with Greengro Technologies and igot420distribution	18-09-18	CI
Gala Pharmaceutical, Inc. Plans to Develop Network of Cannabis Testing Laboratories in an Effort to Capitalize on the Bottleneck Caused by California’S Stringent Cannabis Testing Regulations	18-08-28	CI
Gala Pharmaceutical, Inc. Auditor Raises 'Going Concern' Doubt	18-04-05	CI
Gala Pharmaceutical, Inc. cancelled the acquisition of 51% stake in Cryo Health USA, LLC.	18-02-11	CI
Gala Global Inc. will Change its Name to Gala Pharmaceutical, Inc	18-01-10	CI
Gala Global Inc. will Change its Ticker to GLPH from GLAG	18-01-10	CI
Gala Global Inc. cancelled the acquisition of 80% Controlled Environment Genomics Inc. from Timothy J. Madden.	17-11-29	CI
Gala Global Inc. Announces Management Changes	17-11-29	CI
Gala Global Inc. Names Dr. Maqsood Rehman as COO	17-06-16	CI
Gala Global Inc. announced that it has received $0.26 million in funding from St. George Investments, LLC	17-05-31	CI
Gala Global Inc. announced that it expects to receive $0.26 million in funding from St. George Investments, LLC	17-05-14	CI
Gala Global Inc. Auditor Raises 'Going Concern' Doubt	17-03-08	CI
Gala Global Inc. will Change its Ticker to GLAG from GLAGD	17-02-28	CI
Gala Global Inc. Announces Management Changes	17-02-17	CI

Chart Gala Pharmaceutical, Inc.

Duration

Period

More charts

Company Profile

Gala Pharmaceutical Inc., formerly Gala Global Inc., is engaged in offering plant genomic research, genomic breeding technology, specialty genomic products and laboratory services to agricultural and pharmaceutical sectors. It also provides cGMP (Good Manufacturing Practices) production of active pharmaceutical ingredients (API) for use in clinical trials required to make efficacy claims for varying medical indications. The Company provides operational services and technologies that drive efficiencies in the greenhouse-grown commercial plants and herbs markets.

Sector

Fishing & Farming

More about the company